This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
ZFP36L1 / mRNA decay activator protein ZFP36L1 · Western blot design guide
Design a Western Blot for ZFP36L1
Source-linked ZFP36L1 Western blot protocol options, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-ZFP36L1 WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Evidence assembled September 2026 · For research use; verify linked source records and product datasheet before use
ZFP36L1 Western Blot Experimental Design Guide
Expected bands, source-linked protocol options, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | ~36.3 kDa | |
| Gel | 12–15% (standard starting point) | |
| Positive control | Urinary bladder (IHC candidate; verify WB) +4 more | |
| Negative control | Adipose tissue (IHC candidate; verify WB) |
Important caveats
Reasons your observed band may differ from the expected size.
| PTM | Phosphorylated + Ubl conjugation | |
| Caveat | Modification-state controls | |
| Gene-set association | MSigDB Hallmark membership | |
| Isoform | 1 isoform(s) |
Section 1
Source-Linked ZFP36L1 Western Blot Protocol Options
The A05651 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | various cells (catalog A05651) |
| Gel % | 12–15% (standard starting point) |
| Load | 20–30 µg total protein per lane; optimize for abundance (standard starting point) |
| Transfer | Standard semi-dry transfer; verify efficiency (standard starting point) |
| Membrane | 0.45 µm PVDF (standard starting point) |
| Blocking | 5% milk or 5% BSA in TBST (standard starting point) |
| Primary antibody | A05651; use the WB datasheet starting dilution (standard starting point) |
| Primary incubation | Overnight at 4 °C (standard starting point) |
| Secondary antibody | 1:20000 (catalog A05651) |
| Secondary incubation | 1 h at room temperature (standard starting point) |
| Wash | 3 × 5 min in TBST (standard starting point) |
| Detection | ECL; bracket exposures to avoid saturation (standard starting point) |
Section 2
What Is the Expected ZFP36L1 Western Blot Band Size?
ZFP36L1 is predicted at 36.3 kDa; annotated phosphorylation may affect migration, but no empirical band or visible shift is established.
| Single band near 36.3 kDa | Consistent with the predicted size of ZFP36L1; confirm identity with antibody controls |
| Close doublet near 36.3 kDa | Could reflect different phosphorylation states; a visible shift is unproven |
| Several nearby bands | Could reflect phosphorylation at the annotated serines; band identities need confirmation |
| Weak band in a cytoplasmic fraction | May reflect ZFP36L1 shuttling between cytoplasm and nucleus |
💡Expected ZFP36L1 appearanceZFP36L1 has a predicted mass of 36.3 kDa, with no empirical band size supplied; its phosphorylation sites may affect migration, so confirm any band with antibody specificity controls.
| UniProt predicted mass | Sets a 36.3 kDa reference, not a validated apparent band size |
| Ser54 phosphorylation by MAPKAPK2 | May affect migration; no shift is established |
| Ser90 phosphorylation by PKB/AKT1 | May affect migration; no shift is established |
| Ser92 phosphorylation by PKB/AKT1 and MAPKAPK2 | May affect migration; no shift is established |
| Ser203 phosphorylation by PKB/AKT1 and MAPKAPK2 | May affect migration; no shift is established |
| Situation | Likely cause | Next action |
|---|---|---|
| No band in lysate | ZFP36L1 may be unevenly distributed between nucleus and cytoplasm | Check nuclear and cytoplasmic fractions with an appropriate positive control |
| Band higher than expected | Phosphorylation may alter migration, but the cause is unconfirmed | Compare phosphatase-treated and untreated samples and confirm antibody specificity |
| Band lower than expected | The supplied features do not establish a cleavage product | Check sample integrity and use peptide competition or another antibody to assess identity |
| Multiple bands | Different phosphorylation states are possible; distinct bands are unproven | Compare phosphatase-treated lanes and use peptide competition to identify specific bands |
| Weak or no signal | Expression or recovery in the sampled fraction may be low | Check loading, a positive control, and nuclear and cytoplasmic fractions |
Experiment evidence
Western blot images showing ZFP36L1 band
A05651 · ZFP36L1
A05651 · ZFP36L1
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for ZFP36L1 Western blot
🧪HPA-IHC candidate guidance (verify in WB): For positive controls for ZFP36L1 in Western blot, you can use urinary bladder lysate, the highest-scoring HPA positive tissue.
Positive control: Urinary bladder (IHC candidate; verify WB)
Negative control: Adipose tissue (IHC candidate; verify WB)
Loading controls: Run GAPDH, β-actin, and a total-protein stain such as Ponceau alongside the samples.
⚠️Feasibility: Its intracellular location and an HPA not-detected tissue make tissue lysate controls feasible.
HPA tissue expression evidence for ZFP36L1
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Higher expression tissues · candidate positive controls from IHC
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Urinary bladder | urothelial cells | High | Protein (IHC) | HPA → |
| Breast | glandular cells | Medium | Protein (IHC) | HPA → |
| Epididymis | glandular cells | Medium | Protein (IHC) | HPA → |
| Fallopian tube | glandular cells | Medium | Protein (IHC) | HPA → |
| Gallbladder | glandular cells | Medium | Protein (IHC) | HPA → |
Lower expression tissues · IHC evidence, not confirmed WB-negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | adipocytes | Not detected | Protein (IHC) | HPA → |
| Bone marrow | hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Caudate | glial cells | Not detected | Protein (IHC) | HPA → |
| Cerebellum | cells in granular layer | Not detected | Protein (IHC) | HPA → |
| Cerebral cortex | endothelial cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced ZFP36L1 Western Blot Tips
Deeper troubleshooting and optimisation questions for ZFP36L1, answered from its protein features.
How should ZFP36L1 band migration be interpreted?
Band shift · Use the separately labelled calculated mass and catalog-observed evidence above. A sequence annotation does not establish an observed migration shift. Verify target identity with orthogonal controls.
Could ZFP36L1 isoforms explain multiple bands?
Isoforms · Only one isoform is supplied, with no alternative sequence. These features provide no basis for assigning multiple bands to ZFP36L1 isoforms.
Which phosphorylation sites matter when interpreting ZFP36L1 bands?
PTM · The supplied UniProt coordinates are Ser54 (MAPKAPK2), Ser90 (PKB/AKT1), Ser92 and Ser203 (PKB/AKT1 and MAPKAPK2), Ser318, and Ser334 (RPS6KA1). Check that antibody site numbering uses the same sequence convention. These annotations alone do not predict a visible band shift.
No glycosylation sites are supplied, so the provided features do not support assigning an unexpected band to glycosylated ZFP36L1. Compare the band with the 36.3 kDa prediction and verify antibody specificity before assigning its identity.
No glycosylation sites are supplied, so the provided features do not support assigning an unexpected band to glycosylated ZFP36L1. Compare the band with the 36.3 kDa prediction and verify antibody specificity before assigning its identity.
Does this guide establish induction of ZFP36L1?
Induction · No general induction response is established by this guide. A pathway or gene-set association is not evidence of induction in a particular specimen. Verify the relevant treatment and control in a target-specific experiment.
How should transfer be checked for ZFP36L1?
Transfer · Standard workflow guidance: verify transfer efficiency for the intended target size before interpreting a weak signal. Use total-protein assessment and optimize transfer for the membrane, gel and apparatus; the labelled catalog values take precedence.
How should blocking be optimized?
Blocking · Standard workflow guidance: follow the A05651 datasheet where specified. Otherwise compare 5% milk or 5% BSA in TBST; for a phospho-specific assay start with BSA. Optimize background and specific signal with matched controls.
How should ZFP36L1 be quantified across samples?
Quantitation · Keep sample preparation consistent and quantify the same validated ZFP36L1 band across samples. If using nuclear and cytoplasmic fractions, compare like fractions: ZFP36L1 is listed in both compartments and shuttles between them. Its six annotated phosphorylation sites also warrant care when comparing signals from antibodies with different site recognition.
Where should ZFP36L1 migrate relative to its predicted mass?
Interpretation · Its predicted mass is 36.3 kDa. No observed band position is supplied, so use 36.3 kDa as a starting point rather than an exact migration target. The listed features do not establish a visible shift or explain a difference between apparent and calculated mass.
Yes. ZFP36L1 is listed in the nucleus, cytoplasm, cytoplasmic granules, and P-bodies, and shuttles between nucleus and cytoplasm. Record the fraction used and compare matched fractions when interpreting signal differences.
Start with the 36.3 kDa predicted mass and validate band identity. One isoform is supplied, and phosphorylation is annotated at six UniProt positions, but neither fact establishes the identity or size of an extra band. Consider the sample fraction because ZFP36L1 occurs in both nucleus and cytoplasm.
Yes. ZFP36L1 is listed in the nucleus, cytoplasm, cytoplasmic granules, and P-bodies, and shuttles between nucleus and cytoplasm. Record the fraction used and compare matched fractions when interpreting signal differences.
Start with the 36.3 kDa predicted mass and validate band identity. One isoform is supplied, and phosphorylation is annotated at six UniProt positions, but neither fact establishes the identity or size of an extra band. Consider the sample fraction because ZFP36L1 occurs in both nucleus and cytoplasm.
Boster reagents
ZFP36L1 Western Blot Antibodies
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
Real WB data
Anti-TIS11B ZFP36L1 Antibody
Cat # A05651
The catalog reports A05651, an anti-ZFP36L1 (TIS11B) antibody with reported human, mouse, and rat reactivity. Its Western blot image is described as using various cells and a secondary antibody diluted 1:20,000; the supplied caption does not identify the cells or their species.
Which to pick: A05651 is the only listed option. It has a Western blot image, but check whether its reported reactivity and the image's limited sample details fit your experiment.
Source: BosterBio ZFP36L1 gene-info card — filtered to Western-blot-capable antibodies; each card shows that product's actual WB validation figure.
References
- UniProt Consortium. UniProt entry Q07352.
- Human Protein Atlas. ZFP36L1 tissue expression.
- PMC9948753 — target-verified WB comparison
- PMC13140207 — target-verified WB comparison
- PMC4635361 — target-verified WB comparison